Rheumatoid Arthritis explained: Autoimmunity, Pannus Formation, and Treatments

Overview

In this Osmosis video, rheumatoid arthritis is presented as a systemic autoimmune inflammatory disease that predominantly affects joints but can involve other organ systems. The talk highlights the typical symmetric pattern of joint involvement, early morning stiffness, and potential deformities, setting the stage for understanding diagnosis and treatment.

Key insights

• RA arises from a genetic environmental interplay that leads to citrullination and autoantibody formation (RF and anti CCP).
• Immune cells drive inflammation via cytokines that promote pannus formation and cartilage destruction in the joint.
• Diagnosis relies on clinical signs plus RF and CCP testing, supported by imaging findings.
• Treatment centers on disease modifying antirheumatic drugs and biologics, with NSAIDs and glucocorticoids for flares.

Overview

In this Osmosis video, rheumatoid arthritis (RA) is defined as a chronic systemic inflammatory disorder of autoimmune origin that mainly targets the joints but can involve skin, lungs, and blood vessels. The speaker emphasizes the symmetric joint involvement typical of RA, with the wrists and fingers commonly affected, and underscores how untreated inflammation can lead to progressive joint damage and functional decline.

Joint Anatomy and Normal Physiology

The video reviews how a healthy synovial joint is structured: articular cartilage at the ends of bones provides a smooth, protective cushion, while the synovial membrane lines the joint space and secretes lubricating synovial fluid. A fibrous joint capsule surrounds the joint, and the inner lining contains cells essential for joint homeostasis. This normal anatomy sets the stage for understanding pathological changes in RA.

Genetics and Environmental Triggers

RA arises from an interaction between genetic predisposition and environmental exposures. Specific HLA alleles such as HLADR1 and HLADR4 increase susceptibility. Environmental factors, including cigarette smoking and certain pathogens, can modify self antigens in proteins like type 2 collagen and vimentin through a process called citrullination, generating neoantigens that may be recognized as non self by immune cells.

Immune Activation and Autoantibody Production

Modified self antigens are presented to the immune system, activating CD4+ T helper cells. T cells collaborate with B cells to proliferate and differentiate into plasma cells that produce autoantibodies, notably rheumatoid factor (RF) and anti citrullinated peptide antibodies (CCP). These autoantibodies form immune complexes that accumulate in the synovial fluid and contribute to inflammation and tissue injury.

Cytokines and Joint Destruction

Activated T cells secrete cytokines such as interferon gamma and interleukin 17 that recruit macrophages to the joint. Macrophages release pro inflammatory cytokines including tumor necrosis factor alpha, interleukin 1 and interleukin 6. The cytokine milieu stimulates synovial cells to proliferate, creating a pannus that invades cartilage and bone. Proteases secreted by synovial cells degrade cartilage, exposing bone and leading to erosions. In addition, inflammatory signals increase RANKL expression on T cells, driving osteoclast mediated bone resorption.

Pannus and Bone Erosion

The pannus is a thickened, inflamed synovial membrane composed of fibroblasts, myofibroblasts and inflammatory cells. Its growth and activity erode cartilage and eventually damage bone, contributing to the progressive joint destruction characteristic of RA.

Clinical Features and Diagnosis

RA presents with symmetric joint swelling, warmth, redness, and pain, commonly in small joints such as metacarpophalangeal and proximal interphalangeal joints. Morning stiffness that lasts for extended periods is typical. Over time deformities like ulnar deviation of the fingers or boutonniere and swan neck deformities may occur. Extra articular manifestations include rheumatoid nodules, vasculitis, anemia and lung involvement such as interstitial fibrosis. Diagnosis relies on serology—RF and CCP antibodies—and imaging that shows joint space narrowing, soft tissue swelling and erosions. The combination of clinical features, serology, and imaging solidifies the diagnosis and helps guide therapy.

Treatment and Management

Long term management centers on disease modifying antirheumatic drugs (DMARDs) including methotrexate, hydroxychloroquine and sulfasalazine, which aim to suppress inflammation and slow joint damage. Biologic response modifiers or biologics offer targeted approaches by suppressing T cell activity (abatacept), B cell activity (rituximab), or blocking cytokines such as tumor necrosis factor, interleukin 1 and interleukin 6 with agents like adalimumab, infliximab, etanercept, anakinra, and tocilizumab. For symptom relief during flares non steroidal anti inflammatory drugs and short courses of glucocorticoids are used. The talk also highlights extra articular risks and complex conditions such as felty syndrome, underlining the need for comprehensive care that addresses both joint disease and systemic complications.

Take home messages

RA is a systemic inflammatory autoimmune disease driven by a combination of genetic susceptibility and environmental triggers that promote autoantibody formation and pannus mediated joint destruction. Early recognition and timely, comprehensive treatment with DMARDs and biologics can significantly reduce joint damage and improve quality of life. The video reinforces that managing RA requires attention to both articular symptoms and systemic manifestations to prevent long term disability.